(ECL) Ecolab - Ratings and Ratios
Water Treatment, Cleaning Agents, Sanitizers, Pest Control
Dividends
| Dividend Yield | 0.99% |
| Yield on Cost 5y | 1.26% |
| Yield CAGR 5y | 5.71% |
| Payout Consistency | 93.2% |
| Payout Ratio | 35.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.1% |
| Value at Risk 5%th | 32.0% |
| Relative Tail Risk | -3.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.22 |
| Alpha | -4.61 |
| CAGR/Max DD | 1.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.480 |
| Beta | 0.560 |
| Beta Downside | 0.501 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.26% |
| Mean DD | 3.49% |
| Median DD | 2.32% |
Description: ECL Ecolab December 03, 2025
Ecolab Inc. (NYSE:ECL) delivers water, hygiene, and infection-prevention solutions across four segments: Global Industrial (water treatment, process cleaning for heavy-industry customers), Global Institutional & Specialty (cleaning products for foodservice, hospitality, education, and retail), Global Healthcare & Life Sciences (infection-control and contamination-control solutions for hospitals, pharma, and personal-care firms), and Global Pest Elimination (rodent and insect management for restaurants, hotels, and other commercial venues). The company reaches customers via field sales, corporate account teams, distributors, and dealers, and has operated since 1923 from its Saint Paul, Minnesota headquarters.
Key recent metrics: FY 2023 revenue reached approximately $14.5 billion, with an adjusted EBITDA margin of about 19 % and free-cash-flow conversion near 70 %, supporting a steady dividend yield of ~1.6 % and ongoing share-repurchase programs. Primary economic drivers include rising regulatory scrutiny on water usage and sanitation, accelerated demand for infection-control products post-COVID-19, and broader sustainability mandates that push industrial clients toward closed-loop water-treatment solutions. In the specialty-chemicals sector, Ecolab benefits from a secular shift toward higher-value, service-oriented offerings that generate recurring revenue streams.
For a deeper quantitative dive, the ValueRay platform offers granular metrics and scenario analysis that can help you assess ECL’s upside potential.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.98b TTM) > 0 and > 6% of Revenue (6% = 953.4m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -2.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.37% (prev 8.99%; Δ 9.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 2.63b > Net Income 1.98b (YES >=105%, WARN >=100%) |
| Net Debt (6.87b) to EBITDA (3.43b) ratio: 2.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.21% (target <= -2.0% for YES) |
| Gross Margin 44.32% (prev 43.15%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.09% (prev 70.92%; Δ -1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.58 (EBITDA TTM 3.43b / Interest Expense TTM 282.3m) >= 6 (WARN >= 3) |
Altman Z'' 4.11
| (A) 0.12 = (Total Current Assets 7.11b - Total Current Liabilities 4.19b) / Total Assets 23.90b |
| (B) 0.52 = Retained Earnings (Balance) 12.48b / Total Assets 23.90b |
| (C) 0.12 = EBIT TTM 2.70b / Avg Total Assets 23.00b |
| (D) 0.77 = Book Value of Equity 10.94b / Total Liabilities 14.14b |
| Total Rating: 4.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.28
| 1. Piotroski 6.50pt |
| 2. FCF Yield 1.90% |
| 3. FCF Margin 9.78% |
| 4. Debt/Equity 0.91 |
| 5. Debt/Ebitda 2.00 |
| 6. ROIC - WACC (= 5.76)% |
| 7. RoE 21.58% |
| 8. Rev. Trend 83.03% |
| 9. EPS Trend 81.15% |
What is the price of ECL shares?
Over the past week, the price has changed by -1.17%, over one month by -0.27%, over three months by -4.70% and over the past year by +7.54%.
Is ECL a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 13
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ECL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 291.8 | 11.6% |
| Analysts Target Price | 291.8 | 11.6% |
| ValueRay Target Price | 284 | 8.7% |
ECL Fundamental Data Overview December 05, 2025
P/E Trailing = 37.9784
P/E Forward = 32.0513
P/S = 4.718
P/B = 7.9518
P/EG = 2.9183
Beta = 0.989
Revenue TTM = 15.89b USD
EBIT TTM = 2.70b USD
EBITDA TTM = 3.43b USD
Long Term Debt = 8.05b USD (from longTermDebt, last quarter)
Short Term Debt = 176.5m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.87b USD (from netDebt column, last quarter)
Enterprise Value = 81.84b USD (74.97b + Debt 8.83b - CCE 1.96b)
Interest Coverage Ratio = 9.58 (Ebit TTM 2.70b / Interest Expense TTM 282.3m)
FCF Yield = 1.90% (FCF TTM 1.55b / Enterprise Value 81.84b)
FCF Margin = 9.78% (FCF TTM 1.55b / Revenue TTM 15.89b)
Net Margin = 12.49% (Net Income TTM 1.98b / Revenue TTM 15.89b)
Gross Margin = 44.32% ((Revenue TTM 15.89b - Cost of Revenue TTM 8.85b) / Revenue TTM)
Gross Margin QoQ = 44.79% (prev 44.78%)
Tobins Q-Ratio = 3.42 (Enterprise Value 81.84b / Total Assets 23.90b)
Interest Expense / Debt = 0.63% (Interest Expense 55.3m / Debt 8.83b)
Taxrate = 17.83% (128.0m / 717.7m)
NOPAT = 2.22b (EBIT 2.70b * (1 - 17.83%))
Current Ratio = 1.70 (Total Current Assets 7.11b / Total Current Liabilities 4.19b)
Debt / Equity = 0.91 (Debt 8.83b / totalStockholderEquity, last quarter 9.72b)
Debt / EBITDA = 2.00 (Net Debt 6.87b / EBITDA 3.43b)
Debt / FCF = 4.43 (Net Debt 6.87b / FCF TTM 1.55b)
Total Stockholder Equity = 9.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.30% (Net Income 1.98b / Total Assets 23.90b)
RoE = 21.58% (Net Income TTM 1.98b / Total Stockholder Equity 9.20b)
RoCE = 15.68% (EBIT 2.70b / Capital Employed (Equity 9.20b + L.T.Debt 8.05b))
RoIC = 13.05% (NOPAT 2.22b / Invested Capital 17.03b)
WACC = 7.28% (E(74.97b)/V(83.80b) * Re(8.08%) + D(8.83b)/V(83.80b) * Rd(0.63%) * (1-Tc(0.18)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
[DCF Debug] Terminal Value 79.79% ; FCFE base≈1.73b ; Y1≈1.95b ; Y5≈2.61b
Fair Price DCF = 158.7 (DCF Value 44.94b / Shares Outstanding 283.2m; 5y FCF grow 14.34% → 3.0% )
EPS Correlation: 81.15 | EPS CAGR: 13.68% | SUE: 0.0 | # QB: 0
Revenue Correlation: 83.03 | Revenue CAGR: 5.86% | SUE: 2.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.69 | Chg30d=-0.015 | Revisions Net=-3 | Analysts=14
EPS next Year (2026-12-31): EPS=8.48 | Chg30d=-0.034 | Revisions Net=-4 | Growth EPS=+12.7% | Growth Revenue=+5.2%
Additional Sources for ECL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle